Cachexia - Wasting Disease - Barcelona Conference

H - PLENARY SESSION

Treatment development for cachexia

Chairs:
Mike Tisdale, Birmingham, UK
Akio Inui, Kagoshima, Japan

36. The present, past and future of nutrition and nutraceuticals

Ardy van Helvoort, Wageningen, Netherlands

37. Manipulating the mechanisms controlling appetite and food intake

Daniel Marks, Portland, USA

38. The future of MicroRNAs

Thomas Thum, Hannover , Germany

39. Late-breaking basic science results:
Studies linking epigenetics, nutrition during pregnancy, birth weight with BMI as well as cardiovascular and metabolic diseases in adult life

Berthold Hocher, Berlin, Germany

40. Late-breaking clinical science results:
Cachexia development and genetics

Ken Fearon, Edinburgh, UK

I - CLINICAL TRACK

Clinical Trials: Late breaking approaches

Chairs:
Stefan Anker, Berlin, Germany
Matthias Tschoep, Cincinnati, USA

41. Phase II non-randomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia

Giovanni Mantovani, Cagliary, Italy

42. A phase I, pharmacokinetic (PK) and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer

Stephen Clarke, Sydney, Australia

43. Phase II study of the novel peptide-nucleic acid AVR118 in the management of cancer-related anorexia, cachexia

Martin Chasen, Montreal, Canada

44. Performance improvement in COPD cachexia with SUN11031 (a synthetic human ghrelin) in a placebo-controlled trial

Joseph Gertner, Rochelle Park, USA

45. Age-dependent anti-catabolic effects of exercise training in the skeletal muscle of chronic heart failure patients: results from the Leipzig exercise intervention in chronic heart failure and ageing (LEICA) study

Stephan Gielen, Leipzig, Germany

46. Randomized controlled pilot study of neuromuscular electrical stimulation of the quadriceps in patients with non-small cell lung cancer

Mathew Maddocks, Nottingham, UK

47. Testosterone for heart failure

Giuseppe Rosano, Rome, Italy

48. Direct activation of the skeletal sarcomere by the troponin activator CK-2017357: a novel approach to improving skeletal muscle function

Fady Malik, San Francisco, USA

49. Increases in lean body mass observed with a single dose of ACE-031—a form of the soluble activin receptor type IIB

Jas Seehra, Cambridge, USA

J - BASIC TRACK

Fighting cachexia and sarcopenia

Chairs:
Filippo Rossi Fanelli, Rome, Italy
Luigi Ferrucci, Baltimore, USA

50. Testosterone, frailty and clinical trials

John Morley, St. Louis, USA

51. Cachexia treatment developments: successes and failures

Alessandro Laviano, Rome, Italy

52. Beta-2 agonists

Silvia Busquets, Barcelona, Spain

53. Alternative medicine in cachexia

Joan Vidal-Jové, Barcelona, Spain

54. Exercise, anticatabolic strategies and the treatment of cachexia

Giovanni Mantovani, Cagliari, Italy

K - PLENARY SESSION

Chronic illness & cachexia: common mechanisms

Chairs:
Mitja Lainscak, Golnik, Slovenia
Esther Barreiro, Barcelona, Spain

55. Chronic heart failure

Piotr Ponikowski, Wroclaw, Poland

56. Muscle wasting in COPD

Annemie Schols, Maastricht, Netherlands

57. Chronic kidney disease

Kamyar Kalantar-Zadeh, Torrance, USA

58. Cachexia in stroke and Alzheimer’s disease

Wolfram Doehner, Berlin, Germany

59. Cachexia in liver and bowel diseases

Herbert Lochs, Innsbruck, Austria

L - CLINICAL TRACK

Sarcopenia

Chairs:
Bill Evans, Little Rock, USA
Didier Attaix, Clermont-Ferrand, France

60. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives

Yves Rolland, Toulouse, France

61. Amino acid signaling pathways in skeletal muscle and sarcopenia

Leonard Jefferson, Hershey, USA

62. A life course approach to sarcopenia

Avan Aihie Sayer, Southampton, UK

63. Nutritional interventional studies in the elderly

Antoni Salvà, Barcelona, Spain

64. Inflammation in the elderly

Luigi Ferrucci, Baltimore, USA

M - JUDGES CHOICE

Oral presentations of selected abstracts
Clinical and Basic

Chairs:
Andrew Coats, Sydney, Australia
Alfred Goldberg, Boston, USA

65. Novel effects of myostatin inhibition on skeletal muscles of aging mice: implications for sarcopenia

Kate Murphy, Melbourne, Australia

66. A myostatin decoy receptor prevents loss of muscle mass and function in cancer cachexia

Peter Bialek, Cambridge, USA

67. In vivo antagonism of ActRIIB pathway reverses muscle wasting and prolongs survival in experimental models of cancer cachexia

HQ Han, Thousand Oaks, USA

68. A soluble activin receptor type IIB increases muscle mass in a mouse model of cancer cachexia

Jas Seehra, Cambridge, USA

69. Efficacy of orally available selective melanocortin-4 receptor antagonists in animal models of cancer cachexia

Philipp Weyermann, Liestal, Switzerland

70. Targeting the androgen receptor to treat muscle wasting disorders

Philipp Turnbull, Research Triangle, USA

71. The effects of the catabolic, anabolic transforming agent MT-102 on body weight, body composition, food intake, physical activity and survival compared to imidapril and bisoprolol in a rat model of cancer cachexia

Jochen Springer, Berlin, Germany

72. Attenuation of tumor-induced skeletal muscle atrophy by a zinc-chelator: D-myo-inositol 1,2,6-triphosphate

Steven Russell, Birmingham, UK

73. Effects of HMB on muscle recovery following hind limb suspension in aged rats

Suzette Pereira, Columbus, USA